Nicole J Polman
Overview
Explore the profile of Nicole J Polman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Middelkoop M, Don E, Hehenkamp W, Polman N, Griffioen A, Huirne J
Hum Reprod Update
. 2023 Mar;
29(4):457-485.
PMID: 36857162
Background: Abnormal uterine bleeding (AUB) has a significant socioeconomic impact since it considerably impacts quality of life. Therapeutic options are frequently based on trial and error and do not target...
2.
Polman N, de Haan Y, Veldhuijzen N, Heideman D, de Vet H, Meijer C, et al.
Prev Med
. 2019 May;
125:5-11.
PMID: 31054907
Several countries offer HPV self-sampling for screening non-attendees. It is assumed that screening attendees also prefer self-sampling to clinician-based sampling, however, little research has been conducted with respect to this....
3.
Polman N, Ebisch R, Heideman D, Melchers W, Bekkers R, Molijn A, et al.
Lancet Oncol
. 2019 Jan;
20(2):229-238.
PMID: 30658933
Background: Human papillomavirus (HPV) testing on self-collected samples is a potential alternative to HPV testing on clinician-collected samples, but non-inferiority of its clinical accuracy remains to be assessed in the...
4.
Polman N, Veldhuijzen N, Heideman D, Snijders P, Meijer C, Berkhof J
Int J Cancer
. 2018 Dec;
144(9):2339-2346.
PMID: 30565673
We studied whether triage of human papillomavirus (HPV)-positive women participating in an HPV-based screening programme can be improved by including the HPV result at the previous screen in the triage...
5.
Polman N, Veldhuijzen N, Heideman D, Snijders P, Meijer C, Berkhof J
Br J Cancer
. 2017 Sep;
117(10):1557-1561.
PMID: 28881359
Background: In human papillomavirus (HPV)-based screening, a repeat HPV test is often recommended for HPV-positive women with normal cytology (HPV-pos/cyt-neg), but its absolute risk of cervical precancer (CIN3+) over two...
6.
Veldhuijzen N, Polman N, Snijders P, Meijer C, Berkhof J
Int J Cancer
. 2017 Jul;
141(8):1551-1560.
PMID: 28670823
A main challenge of human papilloma (HPV)-based screening for cervical cancer is to adequately identify HPV-positive women at highest risk of cervical intraepithelial neoplasia grade 3 or worse, CIN3+. The...
7.
Polman N, Uijterwaal M, Witte B, Berkhof J, van Kemenade F, Spruijt J, et al.
Int J Cancer
. 2016 Sep;
140(2):423-430.
PMID: 27677098
Women treated for high-grade cervical intraepithelial neoplasia (CIN) are at risk of recurrent CIN Grade 2 or worse (rCIN2+). Currently, posttreatment monitoring is performed using cytology or cytology/high-risk (hr)HPV cotesting....
8.
Uijterwaal M, Polman N, van Kemenade F, Van Den Haselkamp S, Witte B, Rijkaart D, et al.
Cancer Prev Res (Phila)
. 2015 Mar;
8(6):502-8.
PMID: 25776933
Primary human papillomavirus (HPV)-based cervical screening will be introduced in the Netherlands in 2016. We assessed the 5-year cervical (pre)cancer risk of women with different combinations of HPV and cytology...
9.
Uijterwaal M, Polman N, Witte B, van Kemenade F, Rijkaart D, Berkhof J, et al.
Int J Cancer
. 2014 Oct;
136(10):2361-8.
PMID: 25345358
Primary human papillomavirus (HPV)-based screening results in a 2-5% lower specificity for cervical intraepithelial neoplasia Grade 2 or worse (CIN2+) compared to Pap cytology. To identify HPV-positive women with CIN2+,...